<link rel="stylesheet" href="https://s3.amazonaws.com/aga-lms-assets/styles/master_styles.css">
<div class="row">
  <!-- Left Side Content -->
  <div class="col-md-7">

    <!-- Book -->

    <nav>
      <div class="nav nav-tabs"
      id="nav-tab"
      role="tablist">
      <a class="nav-item nav-link active"
      id="nav-tab-one"
      data-toggle="tab"
      href="#nav-one"
      role="tab"
      aria-controls="nav-one"
      aria-selected="true">Details</a>
      <a class="nav-item nav-link"
      id="nav-tab-two"
      data-toggle="tab"
      href="#nav-two"
      role="tab"
      aria-controls="nav-two"
      aria-selected="false">Credit Information</a>
      <a class="nav-item nav-link"
      id="nav-tab-three"
      data-toggle="tab"
      href="#nav-three"
      role="tab"
      aria-controls="nav-three"
      aria-selected="false">Pricing</a>
    </div>
  </nav>
  <div class="tab-content"
  id="nav-tabContent">
  <div class="tab-pane fade show active"
  id="nav-one"
  role="tabpanel"
  aria-labelledby="nav-tab-one">
  <!-- Tab One -->
  <p>In this on-demand video series, Sophie Balzora, MD, will provide an overview of the concerns patients may
    have about biosimilar therapies, and how best to address those concerns. Role-play is provided to
    demonstrate how to have conversations with your patients who may be beginning treatment with biosimilars,
    or are considering switching to a biosimilar. This activity is a collaboration of the AGA Institute and
    the Crohn's and Colitis Foundation.<br>
  </p>
  <p>Please note that this video mentions one biosimilar, infliximab-dyyb, which has been approved for
    licensure for use of all indications of which infliximab has been approved. As of Dec. 15, 2017, there are
    three therapies biosimilar to infliximab that have been approved for treatment of inflammatory bowel
  disease (IBD): infliximab-abda, infliximab-dyyb and infliximab-qbtx.</p>
  <p>This program is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals,
  Inc. and Pfizer.</p>
  <p class="pt-4 text-center">
    <a href="http://agau.gastro.org/diweb/gateway/init/1/f/catalog*2Fitem*2Feid*2FBIOSIM03"
    class="btn btn-orange"> <i class="fa fa-external-link"></i> Sign in to access</a>
  </p>
  <p><i class="fas fa-info-circle fa-lg"></i>&nbsp;<strong><em>After you sign in, please click the "Launch"
  button on the top of this page to access the videos.</em></strong></p>
  <p class="mt-1">&nbsp;</p>

</div>
<!--~ Tab Two ~-->
<div class="tab-pane fade"
id="nav-two"
role="tabpanel"
aria-labelledby="nav-tab-two">
<!-- Tab Two Content -->
<h3 class="mt-4">CME / Maintenance of Certification (MOC) Information</h3>
<p>The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to
provide continuing medical education for physicians.</p>
<p>The AGA Institute designates this enduring activity for a maximum of .25&nbsp;<em>AMA PRA Category 1
Credits</em>™. Physicians should claim only the credit commensurate with the extent of their
participation in the activity.</p>
<p>In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all
  faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held
  within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts
of interest prior to delivering the educational activity to learners.</p>
<p>Successful completion of this CME activity enables the participant to earn up to .25 MOC points in the
  American Board of Internal Medicine’s (ABIM) MOC program. Participants will earn MOC points equivalent to
  the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to
submit participant completion information to ACCME for the purpose of granting ABIM MOC points.</p>
<p><strong>CME/MOC expiration date: Dec. 22, 2019</strong></p>
<p>If you have any questions, please email&nbsp;<a
 href="mailto:education@gastro.org">education@gastro.org</a></p>
 <h4>Faculty Relationship and Financial Disclosures</h4>
 <p><strong><a
   href="https://cdn.mycrowdwisdom.com/aga/resources/BIOSIM03_What_Patients_Financial_Disclosures2.pdf"
   title=""
   target="_blank">View financial disclosures for presenters, planning committee and staff</a></strong>.
 </p>
 <p><strong>Presenters</strong></p>
 <p>Sophie Balzora, MD, NYU School of Medicine</p>
 <p>Kait Scalisi</p>
 <p><strong><em>Planning Committee</em></strong></p>
 <p>Gary R. Lichtenstein, MD, AGAF, University of Pennsylvania</p>
 <p><strong><em>AGA Staff</em></strong></p>
 <p>Sandra Amos</p>
 <p>Maura H. Davis</p>
 <p>Monique S. Dyson, MS, CHES</p>
 <p>Aimee Frank</p>
 <p>Hannah Herrington, MPH, CHES</p>
 <p>Alison Kim, PhD</p>
 <p>Diana Tsuji, CHES</p>
 <p><strong><em>Crohn’s &amp; Colitis Foundation Staff</em></strong></p>
 <p>Orna Ehrlich</p>
 <p>Anzee Sharp</p>
 <p>Catherine Soto</p>
 <p>Laura Wingate</p>
 <h4 class="pt-3">&nbsp;</h4>
</div>
<!--~ /End Tab Two ~-->

<!--~ Tab Three ~-->
<div class="tab-pane fade"
id="nav-three"
role="tabpanel"
aria-labelledby="nav-tab-three">
<!-- Tab Three Content -->

<table width="50%"
cellpadding="0"
cellspacing="0"
class="table table-bordered">
<thead>
  <tr style="background-color:#102033; color:#FFFFFF;">
    <th width="226"
    align="left"
    scope="col">
    Member
  </th>
  <th width="190"
  align="left"
  scope="col">
  Nonmember
</th>
</tr>
</thead>
<tbody>
  <tr>
    <td>Free (Sign in to access)</td>
    <td>Free (Sign in to access)</td>
  </tr>
</tbody>
</table>
</div>
</div>

<div class="row mt-4">
  <div class="col-md-12">
    <div class="card bg-light mt-3 mb-3">
      <div class="card-body">
        <h4>Learning objectives</h4>
        <p><i class="fa fa-check"></i> &nbsp; Identify approaches to educating and discussing the topic of
        biosimilars with patients.</p>
        <p><i class="fa fa-check"></i> &nbsp; Anticipate common questions from patients about safety,
          appropriate
        use and cost (based on real patient questions received).</p>
        <p><i class="fa fa-check"></i> &nbsp; Employ best practices in shared decision-making to determine
        appropriate course of treatment with patient.</p>


      </div>
    </div>
  </div>
</div>


<div class="row pt-5">
  <div class="container">
    <hr>
    <p>If you have any questions please email the <a href="mailto:education@gastro.org ">AGA Education
    Department</a>.
  </p>
</div>
</div>
</div>

<!-- Right Side Card Content -->
<div class="col-md-5">
  <!-- * Accomidations * -->
  <div class="container mt-3">
    <div class="row ">
      <div class="card text-light card-case"
      style="background-color:rgb(25, 36, 51); width: 20rem">
      <img src="https://s3.amazonaws.com/aga-lms-assets/images/OnDemand_180x180-1547234219168.jpg"
      class="card-img-top bg-light"
      alt="card header image" />
      <div class="card-body">
        <p class="card-text pt-3">
          <i class="fas fa-alarm-clock text-warning fa-2x"></i> Time to Complete: 30 minutes
        </p>

        <p class="card-text pt-3">
          <i class="fas fa-calendar-alt text-warning fa-2x"></i> Released: Dec. 22, 2017
        </p>

        <p class="card-text pt-3">
          <i class="fas fa-hourglass-half text-warning fa-2x"></i> Credit Expires: Dec. 22, 2019
        </p>
        <p class="text-body text-center pt-3">
          <a href="https://cdn.mycrowdwisdom.com/aga/resources/BIOSIM03_What_Patients_Financial_Disclosures2.pdf"
          target="_blank">
          <button class="btn btn-light btn-orange-on-blue"
          style="background-color:#FAA61A; border:1px solid #FAA61A;"> Disclosures
        </button>
      </a> </p>
    </div>
  </div>
</div>
</div>
</div>
</div>

<br />
